Neuragenex Treatment Centers has entered into agreements with ASC Medical Group and American Development Partners®, developers of single-tenant, medical focused, customized rental property build outs, for construction, marketing and operating capital advancement, and leasing of up to 750 treatment centers over the next 5 years.
Neuragenex bills itself as the nation’s fastest growing pain treatment practice and was created in response to the growing need for a non-pharmaceutical, non-surgical, non- invasive pain treatment program. NGX currently operates 13 locations.
The agreement launches the Arizona-based Neuragenex, formed three years ago, on a growth track to develop a 750-clinic nationwide system of primary care-based pain treatment centers.
Under the development agreement ASC and American Development Partners® will provide Neuragenex Treatment Centers with at least 30 qualified practice facilities in 2022, and 96 qualified facilities each year beginning in 2023 until the agreement of 750 locations is completed. The total estimated development value is $2.6 billion. Read more.
